plerixafor has been researched along with Leukocytosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, E; Rewolinski, D | 1 |
| Anagnostopoulos, A; Athanassiadou, A; Batsis, I; Becker, P; Bouinta, A; Constantinou, V; Fassas, A; Jonlin, E; Kaloyannidis, P; Karponi, G; Kotta, K; Papayannopoulou, T; Psatha, N; Stamatoyannopoulos, G; Tahynopoulou, V; Xagorari, A; Yannaki, E; Zervou, F | 1 |
1 trial(s) available for plerixafor and Leukocytosis
| Article | Year |
|---|---|
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
Topics: Adult; Antigens, CD34; Benzylamines; beta-Thalassemia; Cyclams; Female; Genetic Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Hydroxyurea; Immunophenotyping; Leukocyte Count; Leukocytosis; Male; Splenectomy; Treatment Outcome; Young Adult | 2012 |
1 other study(ies) available for plerixafor and Leukocytosis
| Article | Year |
|---|---|
Evaluation of CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization.
Topics: Actins; Animals; Benzylamines; Bruch Membrane; Capillary Permeability; Choroidal Neovascularization; Cyclams; Disease Models, Animal; Female; Flow Cytometry; Fluorescein Angiography; Heterocyclic Compounds; Indoles; Laser Coagulation; Leukocyte Count; Leukocytosis; Morpholines; Rats; Rats, Inbred BN; Receptor Protein-Tyrosine Kinases; Receptors, CXCR4; Wet Macular Degeneration | 2010 |